Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the individual patient’s tumor microenvironment; their strategy to differentiate their approaches to in-licensing as well as combination plays within the area of immuno-oncology; and her thoughts on the exciting potential of the China market.
A company with two main operating sites has to find the best operating model. Oncologie is not simply a company headquartered in the US with a China subsidiary
